Cargando…
Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIAL...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497029/ https://www.ncbi.nlm.nih.gov/pubmed/27930876 http://dx.doi.org/10.1111/jdi.12606 |
_version_ | 1783248087123230720 |
---|---|
author | Yokota, Takashi Kinugawa, Shintaro Hirabayashi, Kagami Suga, Tadashi Takada, Shingo Omokawa, Masashi Kadoguchi, Tomoyasu Takahashi, Masashige Fukushima, Arata Matsushima, Shouji Yamato, Mayumi Okita, Koichi Tsutsui, Hiroyuki |
author_facet | Yokota, Takashi Kinugawa, Shintaro Hirabayashi, Kagami Suga, Tadashi Takada, Shingo Omokawa, Masashi Kadoguchi, Tomoyasu Takahashi, Masashige Fukushima, Arata Matsushima, Shouji Yamato, Mayumi Okita, Koichi Tsutsui, Hiroyuki |
author_sort | Yokota, Takashi |
collection | PubMed |
description | AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIALS AND METHODS: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole‐body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high‐energy phosphates in the calf muscle during plantar‐flexion exercise were measured using (1)proton‐ and (31)phosphorus magnetic resonance spectroscopy, respectively. RESULTS: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post‐ treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post‐treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high‐energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. CONCLUSIONS: Pioglitazone significantly improved the MetS patients’ whole‐body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole‐body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. |
format | Online Article Text |
id | pubmed-5497029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54970292017-07-14 Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome Yokota, Takashi Kinugawa, Shintaro Hirabayashi, Kagami Suga, Tadashi Takada, Shingo Omokawa, Masashi Kadoguchi, Tomoyasu Takahashi, Masashige Fukushima, Arata Matsushima, Shouji Yamato, Mayumi Okita, Koichi Tsutsui, Hiroyuki J Diabetes Investig Articles AIMS/INTRODUCTION: Low aerobic capacity is a strong and independent predictor of all‐cause mortality in patients with metabolic syndrome (MetS). Here, we investigated the effects of pioglitazone treatment on whole‐body aerobic capacity and skeletal muscle energy metabolism in MetS patients. MATERIALS AND METHODS: A total of 14 male patients with MetS received oral pioglitazone 15 mg/day for 4 months. To assess whole‐body aerobic capacity, exercise testing with a bicycle ergometer was carried out before and after pioglitazone treatment. To assess skeletal muscle energy metabolism, intramyocellular lipid in the resting leg and high‐energy phosphates in the calf muscle during plantar‐flexion exercise were measured using (1)proton‐ and (31)phosphorus magnetic resonance spectroscopy, respectively. RESULTS: Pioglitazone significantly increased peak oxygen uptake (25.1 ± 4.9 mL/kg/min pretreatment vs 27.2 ± 3.9 mL/kg/min post‐ treatment, P < 0.05) and anaerobic threshold (12.7 ± 1.9 mL/kg/min pretreatment vs 13.6 ± 1.6 mL/kg/min post‐treatment, P < 0.05), although daily physical activity was comparable before and after the treatment. Intramyocellular lipid content was significantly reduced after pioglitazone treatment by 26%, indicating improved skeletal muscle fatty acid metabolism. Pioglitazone also significantly decreased the muscle phosphocreatine loss during exercise by 13%, indicating improved skeletal muscle high‐energy phosphate metabolism. Notably, the increase in anaerobic threshold; that is, submaximal aerobic capacity, closely correlated with the decrease in intramyocellular lipid content after pioglitazone treatment. CONCLUSIONS: Pioglitazone significantly improved the MetS patients’ whole‐body aerobic capacity and skeletal muscle energy metabolism. The beneficial effect of pioglitazone on whole‐body aerobic capacity might be at least in part through improved fatty acid metabolism in the skeletal muscle. John Wiley and Sons Inc. 2017-01-31 2017-07 /pmc/articles/PMC5497029/ /pubmed/27930876 http://dx.doi.org/10.1111/jdi.12606 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Yokota, Takashi Kinugawa, Shintaro Hirabayashi, Kagami Suga, Tadashi Takada, Shingo Omokawa, Masashi Kadoguchi, Tomoyasu Takahashi, Masashige Fukushima, Arata Matsushima, Shouji Yamato, Mayumi Okita, Koichi Tsutsui, Hiroyuki Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title | Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title_full | Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title_fullStr | Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title_full_unstemmed | Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title_short | Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
title_sort | pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497029/ https://www.ncbi.nlm.nih.gov/pubmed/27930876 http://dx.doi.org/10.1111/jdi.12606 |
work_keys_str_mv | AT yokotatakashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT kinugawashintaro pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT hirabayashikagami pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT sugatadashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT takadashingo pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT omokawamasashi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT kadoguchitomoyasu pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT takahashimasashige pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT fukushimaarata pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT matsushimashouji pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT yamatomayumi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT okitakoichi pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome AT tsutsuihiroyuki pioglitazoneimproveswholebodyaerobiccapacityandskeletalmuscleenergymetabolisminpatientswithmetabolicsyndrome |